WHO ICTRP trial
Clinical study of Mirabegron in the treatment of BPH-related LUTS/OAB
ChiCTR2100047530 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2100047530 |
|---|---|
| Public title | Clinical study of Mirabegron in the treatment of BPH-related LUTS/OAB |
| Scientific title | Clinical study of Mirabegron in the treatment of BPH-related LUTS/OAB |
| Primary sponsor | Qilu Hospital of Shandong University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 4 |
| Countries | China |
| Conditions | Bladder hyperactivity associated with benign prostatic hyperplasia |
| Interventions | Experimental group:Mirabegron + Tamsulosin Hydrochloride;Control group:Tamsulosin hydrochloride |
| Registration date | Jun 20, 2021 |
| Target size | Experimental group:100;Control group:100 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: